Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs

Completed · Phase 2 · Has a placebo group

Conditions studied: Tuberculosis, AIDS-related Complex

In brief

This study will evaluate the lung's immune response to mycobacterium tuberculosis (Mtb) infection and will modulate that response with interferon-gamma.

Key facts

Study ID

NCT00201123

Run by

NYU Langone Health

People needed

89

Starts

2005-04-01

Expected to finish

2007-08-01

Last updated by the study team

2016-12-16

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Positive acid-fast bacillus (AFB) smear within 14 days prior to randomization
• Cluster of Differentiation 4 greater than 200 if HIV positive
• Ability to sign consent
• Bilateral, cavitary pulmonary TB

You may not qualify if…

• Multidrug-resistant (MDR) TB
• Extrapulmonary TB
• HIV positive with opportunistic infection within 30 days of study entry
• Cancer
• Asthma
• Pregnant or lactating women
• Chronic heart disease
• Chronic liver disease
• Chronic renal disease
• Seizure disorder
• Bleeding or clotting disorder
• Diabetes mellitus

Where it is running

• NYU School of Medicine — New York, New York, United States
• The Lung Institute at University of Cape Town — Cape Town, South Africa

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.